This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Welcome

Read time: 270 mins
Last updated:10th Sep 2021
Published:10th Sep 2021

RET inhibitors are an exciting development for non-small cell lung cancer (NSCLC) and thyroid cancers.

  • Discover how RET inhibitors work and review summaries of their efficacy and safety
  • Our leading experts Dr Alexander Drilon and Dr Lori Wirth highlight the importance of testing for RET gene alterations
  • Hear from Professor Fernando Lopez-Rios, an expert pathologist, on improving and interpreting molecular test outcomes
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest